Related Experiment Video

Updated: Nov 30, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K

Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy

Hanzhi Liang1, Jintong Du2, Reham M Elhassan1

  • 1Department of Medicinal Chemistry and Key Laboratory of Chemical Biology of Natural Products (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University , Jinan, Shandong, China.

Expert Opinion on Investigational Drugs
|November 13, 2020
PubMed

Insights

Cyclin-dependent kinase 7 (CDK7) inhibitors show promise as next-generation cancer therapeutics, targeting cell cycle and transcription. Ongoing clinical trials and further research into CDK7 inhibitors are expected to yield effective cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinase 7 (CDK7) is crucial for cell cycle progression and transcriptional regulation.
  • CDK7's role in cancer suggests it is a viable therapeutic target.
  • Selective CDK7 inhibitors are currently in clinical development for cancer treatment.

Purpose of the Study:

  • To review the biological functions of CDK7 and its involvement in cancer.
  • To evaluate the preclinical and clinical advancements of CDK7 inhibitors.
  • To assess the future potential of CDK7 inhibitors in cancer therapy.

Main Methods:

  • Literature search of PubMed and ClinicalTrials databases.
  • Data collection from inception to October 14, 2020.
  • Analysis of preclinical and clinical data for CDK7 inhibitors.

Main Results:

  • CDK7 inhibitors are emerging as a significant therapeutic strategy in oncology.
  • Several selective CDK7 inhibitors, including SY-5609 and CT7001, are in clinical trials.
  • Evidence supports CDK7's role as a promising target for various cancers.

Conclusions:

  • CDK7 inhibitors represent a promising next-generation approach to cancer treatment.
  • Challenges remain, including selectivity, managing side effects, and overcoming drug resistance.
  • Continued clinical development and target analysis will solidify CDK7 inhibitors' role in future cancer therapy.
Keywords:
CDK7 inhibitorCyclin dependent kinase 7anti-cancercell cycletranscriptional addiction

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.1K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.3K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
125.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K